Evolus rises on upbeat prelim Q4 revenue

Evolus

17/01/2024 13:29

** Cosmetic drug maker Evolus'  EOLS.O  shares rise 8% to
$11.26 premarket
    ** Company reports prelim Q4 revenue of $61 mln vs est
$58.54 mln - LSEG
    ** Says Q4 revenue driven primarily by higher volumes from
market share gains
    ** Company expects 2024 net revenue between $255 mln and
$265 mln; vs est $257.5 mln
    ** Company's shares rose ~40% in 2023

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))